EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

VCP activator reverses nuclear proteostasis defects and enhances TDP-43 aggregate clearance in multisystem proteinopathy models

Jessica M Phan, Benjamin C Creekmore, Aivi T Nguyen, Darya D Bershadskaya, Nabil F Darwich, Carolyn N Mann, Edward B Lee

Journal of Clinical Investigation · 2024

DOI: 10.1172/jci169039 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2024. Verfasst von Jessica M Phan und 6 weiteren Autor:innen. Hauptthemen laut MEDLINE: DNA-Binding Proteins, Myositis, Inclusion Body, Proteostasis, Valosin Containing Protein. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NIGMS NIH HHS, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pathogenic variants in valosin-containing protein ( VCP ) cause multisystem proteinopathy (MSP), a disease characterized by multiple clinical phenotypes including inclusion body myopathy, Paget’s disease of the bone, and frontotemporal dementia (FTD). How such diverse phenotypes are driven by pathogenic VCP variants is not known. We found that these diseases exhibit a common pathologic feature: ubiquitinated intranuclear inclusions affecting myocytes, osteoclasts, and neurons. Moreover, knock-in cell lines harboring MSP variants show a reduction in nuclear VCP. Given that MSP is associated with neuronal intranuclear inclusions comprised of TDP-43 protein, we developed a cellular model whereby proteostatic stress results in the formation of insoluble intranuclear TDP-43 aggregates. Consistent with a loss of nuclear VCP function, cells harboring MSP variants or cells treated with VCP inhibitor exhibited decreased clearance of insoluble intranuclear TDP-43 aggregates. Moreover, we identified 4 compounds that activate VCP primarily by increasing D2 ATPase activity, where pharmacologic VCP activation appears to enhance clearance of insoluble intranuclear TDP-43 aggregate. Our findings suggest that VCP function is important for nuclear protein homeostasis, that impaired nuclear proteostasis may contribute to MSP, and that VCP activation may be a potential therapeutic by virtue of enhancing the clearance of intranuclear protein aggregates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA-Binding ProteinsMyositis, Inclusion BodyProteostasisValosin Containing ProteinAnimalsHumansMiceCell NucleusFrontotemporal DementiaIntranuclear Inclusion BodiesOsteitis DeformansProtein AggregatesTDP-43 Proteinopathies

Stichwörter der Autor:innen

Genetic diseasesNeurodegenerationNeurosciencePharmacologyTherapeutics

Substanzen

DNA-Binding ProteinsProtein AggregatesTARDBP protein, humanValosin Containing ProteinVCP protein, human

Förderung

  • NIA NIH HHS
  • NIGMS NIH HHS
  • NIH
  • NIA

Zitieren

APA

Phan, J. M., Creekmore, B. C., Nguyen, A. T., Bershadskaya, D. D., Darwich, N. F., Mann, C. N., & Lee, E. B. (2024). VCP activator reverses nuclear proteostasis defects and enhances TDP-43 aggregate clearance in multisystem proteinopathy models. Journal of Clinical Investigation. https://doi.org/10.1172/jci169039

Vancouver

Phan JM, Creekmore BC, Nguyen AT, Bershadskaya DD, Darwich NF, Mann CN, et al. VCP activator reverses nuclear proteostasis defects and enhances TDP-43 aggregate clearance in multisystem proteinopathy models. Journal of Clinical Investigation. 2024. doi:10.1172/jci169039

BibTeX
@article{Phan2024,
  author = {Phan, Jessica M and Creekmore, Benjamin C and Nguyen, Aivi T and Bershadskaya, Darya D and Darwich, Nabil F and Mann, Carolyn N and Lee, Edward B},
  title = {VCP activator reverses nuclear proteostasis defects and enhances TDP-43 aggregate clearance in multisystem proteinopathy models},
  journal = {Journal of Clinical Investigation},
  year = {2024},
  doi = {10.1172/jci169039}
}
Kostenlos starten →